大东方拟出售金华联济80%股权及相关债权

Core Viewpoint - The company, Da Dongfang, announced the transfer of 80% equity and debt claims of Jinhua Lianji Hospital to Jinhua Lin Tian Biotechnology Co., aiming to optimize its healthcare service business structure due to ongoing losses since acquisition [1] Group 1: Transaction Details - Shanghai Junyao Medical Health Technology Co., a subsidiary of Da Dongfang, plans to transfer 80% of its equity in Jinhua Lianji Hospital for 1 yuan [1] - The debt claims held by Junyao Medical against Jinhua Lianji amount to approximately 89.991 million yuan, which will be transferred for 5.8 million yuan [1] Group 2: Financial Performance - Since the acquisition in March 2022, Jinhua Lianji Hospital has incurred cumulative losses of 79.15 million yuan up to September 2025 [1] - The hospital has not reached a break-even point due to changes in the market environment and healthcare policies since 2022 [1] Group 3: Strategic Intent - The company aims to enhance service scale and operational efficiency through a professional management team and market-oriented operations [1] - The transfer of equity and debt is part of a strategy to optimize the asset structure and improve the quality and efficiency of the healthcare business segment [1]